Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

1articles mentioning drugs

1drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: ranibizumab pro re nata ×

ranibizumab pro re nata

This drug is selected. Its supporting articles are shown below.

ranibizumab pro re nata1

Articles mentioning ranibizumab pro re nata

1 articles · page 1 of 1

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

bjophthalmol · abstract · 2025-12-15 · 1 matching annotations

95.1%

ranibizumab aflibercept ranibizumab pro re nata neovascular age-related macular degeneration

… (95% CI) difference of −6.53 (−12.47 to −0.58 µm) in favour of ranibizumab (23.53 (18.58 to 28.49) µm) versus aflibercept (30.06 (25.04 to…